Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib in Pediatric MATCH (Arm G)
NCT03220035Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2017
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of vemurafenib in solid tumor, non-Hodgkin lymphoma (NHL), histiocytic disorders, sponsored by National Cancer Institute. Started Nov 2017; status: completed.
02
Drugs
vemurafenib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)histiocytic disorders
Beyond the preview
Go deeper on NCT03220035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220035.